Dear IH CYDY Board, I am upwithstock on Subreddit LT and

New Post Public Reply Private Reply Replies (2) Message Board
MLAB
1,496
Dear IH CYDY Board,
I am upwithstock on Subreddit LT and Livimmune
I have not posted here before, mainly because for me it has not been a user friendly experience. But occasionally I come here to read mainly ohm20; but I scan thru other posts from time to time and happen to see some posts that don't really seem to know the FDA process but comment on like they do. Plus, they don't seem to understand what has to be in place if you submit a BLA.

Any pharma company that submits a BLA, especially their first one (CYDY?), can be audited before the BLA is fully accepted or right after to see if the company is in FULL compliance with all things FDA. So what does that really mean? There are BOAT LOADS of quality documents that need to be in place for the drug, the CMC, the surveillance of trials and if approved a surveillance program for tracking complaints, adverse events and other possible quality issues. Like sterility, packaging, shipping container issues that could contaminate to product on the inside. All formulary documentation and I am not exaggerating when I say this but there is a ton more quality systems stuff that would blow your mind. Not even the safety data and trial data.

Why is this knowledge important? People don't seem to understand WHY, Cyrus pulled the HIV BLA back. The third party consultants that were hired and they were ex-FDA reviewers basically said if CYDY would submit a BLA, CYDY would not survive the AUDIT the FDA would surely do, because it would have been our first BLA submnission. Those generally get audited to make sure that all of the stuff I mentioned above and all of the other stuff I have not mentioned are in place and up to date. NP may of had 10% of this in place thanks to Nite Ray and the CMC data.
Because the audit team clearly saw nothing else was even close, they recommend to Cyrus to pull the HIV bLa submission. SMART MOVE.

But the third party auditors were not done working on all of the Amarex crap. Long story short, the auditors were able to validate the RAW DATA. This is the data that is cloected by clinicians that interface with the patients collect and eventually put into the electronic files. The CRO does not do that. They takle the electronic data and then basically agregate it and then they are supposed to put it the correct format. They are also supposed to follow strict surveillance protocols and other things. Amarex obviously failed all that. But, the data and the safety was intact. That is why Cyrus changed course and started talking more about HIV and HIV was mentioned more and more in SEC filings which I reference a TON in my posts. IMO and other familiar with BLA filings that the majority of the documents and other documents CYDY was working on are for passing a BLA submission audit. We HAVE NO DOUBTS ABOUT THAT. The clinical hold will be lifted and we feel based on experience that a BLA resubmission will happen at a minimum.

Regarding PIVOTAL TRIALS. geez... just look it up. The FDA and the sponsor in this case CYDY have reported that the HIV - MDR phase 2b/3 trial is a PIVOTAL TRIAL.Its in the 10K!! Meaning that the results would be submitted with the BLA submission and that trials data would be used to vote and yes or no at the PDUFA review. SO everything technically was achieved in the PIVOTAL TRIAL accept the freaking CRO screwed us.

Therefore, with all of the recent discoberies of the shennigans that the FDA pulled with Suzanne Strayhorn and Amarex screwing us. The FDA had the UNUSUAL PDUFA-likje panel meeting. The only thing different about that meeting is: it was not public (PDUFA meetings are public) and there was not vote of yes or no...as far as we know. IMO, the FDA has a credibility issue and also understands that CYDY got screwed from multiple directions. Since there seems to be unprecedent FDA failings and they don't want this to go public. it already has, but they have been help Cyrus with all of the other things CYDY needs to have in place to pass a BLA audit.

This has attributed to the length of time it has taken to get to this point and iMO CYDY had to be silent about a lot of this shit.

My apologies for Capital letters but I have been misquoted too many times. I wish all the longs the very best. Most importantly I hope and pray that CYDY can move forward and get LL into physicians hands to start treating patients in need. I thank you all for your patience with this long post.
Happy Thanksgiving from MLAB/Upwithstock

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenworks Mower Snags Best Electric Award for 2026

Updated Category News Views 34

Greenworks Strikes Again with Top Lawn Mower Honors Man, when I think about the evolution from noisy, gas-guzzling lawn mowers to sleek, battery-powered beasts, Greenworks is right there, leading the charge. Just the other day, Popular Mechanics singled out the Greenworks 80V 22-inch Cordless Lawn Mower, handing it the coveted title of Best Electric Lawn Mower for 2026....

Continue Reading
Taiwan's T+ MedIC: Launching AI-Driven Health Tech

Updated Category News Views 31

A New Wave of Healthcare Innovation in Taiwan Listen up, because something interesting is brewing in Taiwan's healthcare sector. Not the kind of shenanigans cooked up by Wall Street, but a genuine shot at transforming patient care. The T+ MedIC Medical Innovation Accelerator has just crowned its first winners, and we're talking a whole new level of medical tech...

Continue Reading
vVARDIS Readies for Big Day on NYSE—IPO Set to Shine

Updated Category News Views 73

vVARDIS Stepping into the Spotlight of the NYSE Alright, folks, here's one that could make some waves. vVARDIS is gearing up for its NYSE debut, trading under the ticker VVVV. They're no small fry talking about 9.72 million shares priced at 18 bucks a pop. This isn't just any run-of-the-mill company; they claim to have the first peptide-containing formulation for early...

Continue Reading
Global Case Studies in Poverty Reduction Spotlighted

Updated Category News Views 94

A Fresh Spotlight on Poverty Reduction Efforts Amid the clamor of social and economic challenges, 126 stellar case studies of poverty reduction just took center stage at a seminar in Beijing. These admired initiatives emerged from the seventh global solicitation, chosen from a pile of 890 entries submitted by do-gooders and organizations spanning 31 countries. If you've...

Continue Reading
Canadian Solar Gears Up for Q3 2026 Earnings Call

Updated Category News Views 7

Canadian Solar Prepares for Earnings Disclosure Well, strap in, folks. Canadian Solar Inc. (NASDAQ: CSIQ)—a staple in the solar arena—announced that they'll unveil their third quarter 2026 financials on December 3. It's going to be a call worth dialing into. They're holding it right at 8:00 a.m. Eastern Time. You can pop over to their website for a live webcast or go...

Continue Reading
DeFi Tech Q3 2026: Navigating Cash Strong Waters

Updated Category News Views 61

DeFi Technologies: Holding Steady as Markets Sway DeFi Technologies Inc. has just thrown its quarterly earnings into the ring. With $18.3 million in revenue and a net income of $22.3 million, this digital asset dynamo is showing signs of resilience, even as the financial seas continue their wild dance. For those of us watching the NASDAQ:DEFT like hawks, these figures...

Continue Reading
K-Jeonnam Gim Debuts on Amazon: Korean Seaweed Arrives

Updated Category News Views 75

Korean Seaweed Ventures to the US Market Alright, folks, here's a twist for your snack drawer—Korean seaweed making waves right on Amazon's virtual shelves! Shinan 1004 Seaweed Co. is shaking things up with their brand spankin' new K-Jeonnam Gim. This ain't just any old sea greens we're talking about. We're dealing with crispy, roasted sheets bursting with savory, nutty...

Continue Reading
APEC Summit 2026: Shenzhen in the Spotlight

Updated Category News Views 35

An International Stage for Shenzhen Alright, folks, here's the deal. We’ve got the 2026 APEC Summit rolling into Shenzhen, perched right there in Guangdong Province, and the world’s eyes are glued to it. Happens November 18–19, and you better believe it’s a magnet for all things global. The China Media Group’s Chinese Global Program Center isn’t missing a...

Continue Reading
ACR Poker's $20M OSS: Stakes High on Sunday Action

Updated Category News Views 89

ACR Poker Takes the Spotlight with a Mammoth Sunday Sunday, November 15 is about to be a slugfest over at ACR Poker, as players gear up for an intense day of card-shuffling and betting. We’re looking at flights for all four headlining events of the Online Super Series (OSS) right alongside day two of The Quattro and an eye-popping WSOP Paradise Mega Satellite blowing...

Continue Reading
Biodiversity Monitoring Poised for $11.39 Billion Boom

Updated Category News Views 105

A Billion-Dollar Market on the Rise Picture this: you're watching the world make a monumental shift towards sustainability in real-time. The biodiversity monitoring market is on a gallop, poised to grow from a modest USD 7.17 billion in 2026 to a hearty USD 11.39 billion by 2031. That's a CAGR of 9.7%—a pace that soothes the nerves of any investor weary of the whims of...

Continue Reading

Top 5 Most Recently Viewed Articles

VILNIAUS BALDAI AB: Major Decisions Ahead for Shareholders

Updated Category News Views 267

Upcoming Resolutions for VILNIAUS BALDAI AB Shareholders The Management Board of VILNIAUS BALDAI AB has set forth exciting draft resolutions for the Annual General Shareholders meeting. This gathering promises to be significant as it highlights the company’s performance and future direction. Consolidated Management and Auditor Reports Shareholders will be presented with...

Continue Reading
Precigen's PAPZIMEOS Receives FDA Approval for RRP Treatment

Updated Category News Views 215

Precigen's Revolutionary FDA Approval of PAPZIMEOS PAPZIMEOS has made history as the first and only FDA-approved therapy for adults suffering from recurrent respiratory papillomatosis (RRP). This remarkable achievement brings significant hope and therapeutic options for patients enduring this challenging condition. Understanding PAPZIMEOS and Its Impact Recently, the U.S....

Continue Reading
Brunswick Corporation's Stock Struggles in Challenging Market

Updated Category News Views 200

Brunswick Corporation Faces Market Turmoil Brunswick Corporation (NYSE: BC) has recently reached a troubling milestone, hitting a 52-week low of $63.05 amid a tumultuous market landscape. As an established name in the recreational products sector, Brunswick is recognized for its diverse portfolio that includes marine engines, boats, and fitness equipment. The current...

Continue Reading
Larimar Therapeutics Shares Latest Financial Insights and Updates

Updated Category News Views 273

Larimar Therapeutics Financial Report Highlights BALA CYNWYD, Pa. — Larimar Therapeutics, Inc. (Nasdaq: LRMR), a clinical-stage biotechnology company dedicated to developing innovative treatments for complex rare diseases, has shared notable updates regarding its financial performance and operational progress. The third quarter of 2024 has been significant for the...

Continue Reading
Understanding Sogeclair's Voting Rights Overview for 2025

Updated Category News Views 170

Overview of Sogeclair's Corporate Structure SOGECLAIR is a prominent business corporation with its headquarters situated at 7 avenue Albert Durand in Blagnac, France. With a registered capital of €3,204,901, the company operates under the registration number 335 218 269 in Toulouse. As a public corporation, SOGECLAIR plays a significant role in its industry, making it...

Continue Reading